^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR exon 19 deletion + MET amplification

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956; 4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. (PubMed, Clin Cancer Res)
    Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive EGFR-mutant NSCLC.
    Clinical • P1 data • Journal • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR amplification • EGFR C797S • EGFR L858R + EGFR T790M • EGFR C797S + EGFR T790M + EGFR L858R • EGFR C797S + EGFR T790M + EGFR exon 19 deletion • EGFR positive • MET amplification + EGFR mutation • EGFR T790M + EGFR C797S • EGFR exon 2-7 deletion + EGFR amplification • EGFR mutation + EGFR T790M • EGFR exon 19 deletion + MET amplification • EGFR mutation + EGFR T790M + EGFR C797S • EGFR T790M + exon 19 deletion
    |
    Tagrisso (osimertinib)